A global consumer healthcare leader delivering sustainable above market growth and attractive returns
DISCLAIMER

NOT FOR RELEASE, PUBLICATION, DISTRIBUTION OR FORWARDING, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL. BY ATTENDING THE MEETING WHERE THIS PRESENTATION IS MADE, OR BY READING THE PRESENTATION SLIDES, YOU ACKNOWLEDGE AND AGREE TO COMPLY WITH THE FOLLOWING RESTRICTIONS.

This presentation (the "Presentation") has been prepared and issued by and is the sole responsibility of GlaxoSmithKline plc (the "Company" or "GSK"). The Presentation has been prepared, and access to it has been granted to you, solely for your information in connection with the proposed demerger by GSK of its consumer healthcare business ("Consumer Healthcare"). For the purposes of this notice, "Presentation" means this document, its contents or any part of it, any oral presentation, any question and answer session and any written or oral material discussed or distributed during the Presentation meeting.

The Presentation and the information contained herein must not be recorded, taken away, disclosed, copied, distributed, reproduced, transmitted or passed on, directly or indirectly, in whole or in part, to any other person or published in whole or in part, for any purpose or under any circumstances, without the prior written consent of the Company, Citigroup Global Markets Limited ("Citi"), Goldman Sachs International ("Goldman Sachs") and Merrill Lynch International ("BofA Securities" and, together with Citi and Goldman Sachs, the "Banks").

No person is authorised to give any information or to make any representation not contained in and not consistent with the Presentation and, if given or made, such information or representation must not be relied upon as having been authorised by, or on behalf of, the Company or the Banks. The information set out in this Presentation does not constitute or form part of, and should not be construed as, any recommendation for the taking of any action, the acquisition of any asset or any securities.

This Presentation does not constitute or form part of any offer or invitation to purchase, acquire, subscribe for, sell, dispose of or issue, or any solicitation of any offer to purchase, acquire, subscribe for, sell or dispose of, any security, including shares of GSK, shares of the new holding company of Consumer Healthcare ("Haleon") or any other securities of GSK, CH or their respective subsidiaries.

If any such securities are offered or sold in the future, they will not be offered or sold in the United States absent registration under the US Securities Act of 1933, as amended (the "Securities Act"), or an applicable exemption from the registration requirements of the Securities Act.

This Presentation is directed only at persons: (a) in member states of the European Economic Area who are "qualified investors" within the meaning of Article 2(e) of Regulation (EU) 2017/1129; (b) in the United Kingdom who (i) have professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or fall within Article 49(2)(a) to (d) of the Order; and (ii) are "qualified investors" within the meaning of Article 2(e) of the UK version of the Regulation (EU) 2017/1129 as it forms part of retained EU law as defined in and by virtue of the European Union (Withdrawal) Act 2018; and (c) to whom they may otherwise lawfully be communicated (all such persons in (a), (b), and (c) together being referred to as "Relevant Persons"). It is a condition of your receiving the Presentation that you are a Relevant Person.

No representation, warranty or undertaking, express or implied, is or will be made or given and no responsibility or liability is or will be accepted by the Company or any of the Banks or any of their respective affiliates or any of their respective representatives in relation to the truth, adequacy, accuracy, completeness or reasonableness of the information and opinions contained in, or the use of, the Presentation (or whether any information has been omitted from the Presentation), or as to any such information or opinions remaining unchanged after the Presentation is issued (and no-one is authorised to do so on behalf of any of them).

The Company, each of the Banks and their respective affiliates and representatives disclaim, to the maximum extent permitted by law, any responsibility or liability, whether express or implied, arising in tort, contract or otherwise, for the Presentation and any information and opinions contained therein, or any errors, omissions or misstatements contained in the Presentation.
DISCLAIMER cont.

Except where otherwise indicated in the Presentation, the information provided herein is based on matters as they exist as of the date of preparation of the Presentation and not as of any future date. All information presented or contained in the Presentation is subject to verification, correction, completion and change without notice. None of the Company or any of the Banks or any of their respective affiliates or any of their respective representatives undertakes any obligation to amend, correct, keep current or update the Presentation or to provide the recipient with access to any additional information that may arise in connection with it. The Presentation does not constitute an audit or due diligence review and should not be construed as such. No reliance may be placed for any purposes whatsoever on the information contained in the Presentation or on its truth, adequacy, accuracy, completeness or reasonableness.

In addition, the Presentation contains certain statements that are, or may be deemed to be, “forward-looking statements” with respect to current expectations and projections about future events, strategic initiatives and future financial condition and performance relating to Consumer Healthcare and/or GSK. These statements sometimes use words such as “expects”, “anticipates”, “believes”, “targets”, “plans”, “intends”, “projects”, “indicates”, “may”, “will”, “should” and words of similar meaning (or the negative thereof). These forward-looking statements include all matters that are not historical facts. These include, but are not limited to, statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, dividend payments and financial results.

They appear in a number of places in the Presentation. Any forward-looking statements made by or on behalf of the Company speak only as of the date they are made and are based upon the knowledge and information available to the Directors on the date of this Presentation. These statements and views may be based on a number of assumptions and, by their nature, involve unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future and/or are beyond the Company’s control or precise estimate. Such factors include, but are not limited to, those discussed under ‘Principal risks and uncertainties’ on pages 261 to 275 of GSK’s Annual Report for 2020 and any impacts of the COVID-19 pandemic.

Such forward-looking statements are not guarantees of future performances and no assurance can be given that any future events will occur, that projections will be achieved or that the Company’s assumptions will prove to be correct. Actual results may differ materially from those projected, and (other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, the UK Listing Rules and the Disclosure and Transparency Rules of the Financial Conduct Authority (“FCA”)), the Company does not undertake to revise any such forward-looking statements to reflect new information, future events or circumstances or otherwise. You should, however, consult any additional disclosures that the Company may make in any documents which it publishes and/or files with the SEC and take note of these disclosures, wherever you are located. These forward-looking statements speak only as of the date of the relevant document. Undue reliance should not be placed on these forward-looking statements. Except as required by applicable law or regulation, each of the Company and the Banks expressly disclaims any obligation or undertaking to release any updates or revisions to these forward-looking statements.

No statement in the Presentation is or is intended to be a profit forecast or profit estimate.

Certain figures contained in this Presentation, including financial information, have been subject to rounding adjustments. Accordingly, in certain instances, the sum or percentage change of the numbers contained in this Presentation may not conform exactly with the total figure given.

Certain financial information contained herein has not been audited, comforted, confirmed or otherwise covered by a report by independent accountants. When and if audited financial information is published or becomes available, the data could vary from the data set forth herein. In addition, past performance cannot be relied on as a guide to future performance.

All outlooks, targets, ambitions and expectations regarding future performance and the dividend, as well as the medium term outlooks and 2022 considerations, should be read together with this disclaimer and the Appendix at the end of this Presentation.
DISCLAIMER cont.

Unless otherwise stated, statements of market position are on the basis of sales to consumers in the relevant geographic market or product category in 2020, as reported by: (i) in the case of statements relating to OTC/VMS, Nicholas Hall’s DB6 Consumer Healthcare Database at manufacturer’s selling prices; and (ii) in the case of statements relating to Oral Health, Euromonitor Passport at manufacturer’s selling prices. The value of a geographic market or product category and market size are provided on the basis of sales to consumers in 2020 in the relevant market or product category, as reported by: (i) in the case of statements relating to OTC/VMS, Nicholas Hall’s DB6 Consumer Healthcare Database at manufacturer’s selling prices; and (ii) in the case of statements relating to Oral Health, Euromonitor Passport at manufacturer’s selling prices.

The Company confirms that all third-party data contained in this Presentation has been accurately reproduced and, so far as the Company is aware and able to ascertain from information published by that third party, no facts have been omitted that would render the reproduced information inaccurate or misleading.

Where third-party information has been used in this Presentation, the source of such information has been identified.

While industry surveys, publications, consultant surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, the accuracy and completeness of such information is not guaranteed. The Company has not independently verified any of the data obtained from third-party sources (whether identified in this Presentation by source or used as a basis for the Directors’ beliefs and estimates), or any of the assumptions underlying such data. Similarly, internal surveys, industry forecasts and market research, which the Company believes to be reliable, have not been independently verified.

This Presentation includes trademarks, trade names and trade dress of other companies. Use or display by us of other parties’ trademarks, trade names or trade dress or products is not intended to and does not imply a relationship with, or endorsement or sponsorship of us by, the trademark, trade name or trade dress owners. Solely for the convenience of investors, in some cases we refer to our brands in this Presentation without the ® symbol, but these references are not intended to indicate in any way that we will not assert our rights to these brands to the fullest extent permitted by law.

Any product claims which appear in this Presentation are only intended for audiences in the territories for which they were created. Product descriptions and product claims which appear in this Presentation may not be available or applicable in other territories. The Company makes no representation that such material is appropriate for use outside of the original intended territory and nothing in this Presentation should be construed as providing any kind of medical advice or recommendation, and should not be relied on as the basis for any decision or action.

Each of the Banks is authorised by the Prudential Regulation Authority ("PRA") and regulated in the United Kingdom by the PRA and the FCA. Each of the Banks will not regard any other person (whether or not a recipient of the Presentation) as a client and will not be responsible to anyone other than GSK and Haleon for providing the protections afforded to its clients or for giving advice in relation to any transaction, arrangement or other matter referred to in the Presentation.

A number of Adjusted measures are used to report the performance of our business, which are non-IFRS measures. Adjusted results, CER and other non-IFRS measures may be considered in addition to, but not as a substitute for or superior to, information presented in accordance with IFRS. These measures are defined and set out in the “Glossary” slide at the end of this presentation. Reconciliations to the nearest IFRS measure are included in the Appendix and will be provided as part of the Haleon prospectus.
Global leader 100% focused on consumer healthcare with clear purpose

Exceptional portfolio of category leading brands with attractive footprint and competitive capabilities

**Strategy to outperform** and run a responsible business, integral to all we do

**4-6% organic annual sales growth**, sustainable moderate margin expansion and high cash conversion

**Attractive growth profile** with capacity to invest and deliver shareholder returns

---

1. Organic annual sales growth (see appendix for definition), in the medium term
2. Adjusted operating margin, in the medium term at CER
3. Free cash flow conversion (see appendix)
Highly experienced management team

- Brian McNamara
  Chief Executive Officer
- Tobias Hestler
  Chief Financial Officer
- Tamara Rogers
  Chief Marketing Officer
- Franck Riot
  Head of Research and Development
- Lisa Paley
  Head of U.S. and North America
- Keith Choy
  Head of Asia Pacific
- Filippo Lanzi
  Head of EMEA and LatAm
- Teri Lyng
  Head of Sustainability
- Amy Landucci
  Chief Digital and Technology Officer
- Bart Derde
  Head of Quality and Supply Chain
- Jooyong Lee
  Head of Strategy
- Dana Bolden
  Head of Global Corporate Affairs
- Mairéad Nayager
  Chief Human Resources Officer
- Bjärne Philip Teilmann
  General Counsel
Exceptional brands

- Sensodyne
- Voltaren
- Centrum
- Parodontax
- Panadol
- Otrivin
- Poligrip
- Advil
- Theraflu
- Dr. Best
- Excedrin
- ChapStick
- Tums
- Grand-Pa
- Emergen-C
- Eno
- Fenbid
- Caltrate

Haléon
Deliver better everyday health

with humanity
Track record of strong performance

**Haleon portfolio revenue growth (%)**

- 2020: 4.9%
- 2021: 3.9%

**Adjusted operating margin (%)**

- 2019: 19.5%
- 2020: 21.0%
- 2021: 22.8%

**Underlying free cash flow (£bn)**

- 2019: 0.8
- 2020: 1.6
- 2021: 1.4

4.4% **CAGR**\(^1,3\) despite -50bps impact of low cold and flu

Successful **completion of integration and separation on track**

**Synergy delivery > expectations**

Strong focus on cost control driving **efficiencies across the business**

**Investment** in A&P, R&D, capabilities

**High cash conversion**\(^3\)

Good working capital and **cash management**

---

\(^1\) Haleon portfolio revenue growth. See glossary. 12 months of Pfizer brand revenues included in 2019, 2020 and 2021. Divested brand revenues excluded from 2019, 2020 and 2021.

\(^2\) Underlying free cash flow excluding separation, admission and restructuring costs and net proceeds from disposals

\(^3\) 2019-2021, free cash flow conversion (see appendix)
Clear approach to deliver growth ambitions

World class portfolio + Competitive capabilities + Strategy to outperform → Growth ambitions

4-6% organic annual sales growth\(^1\)

Expanding margin\(^2\) while investing for growth

High cash conversion\(^3\)

Disciplined capital allocation

---

1. Organic annual sales growth (see appendix for definition), in the medium term
2. Adjusted operating margin, in the medium term at CER
3. Free cash flow conversion (see appendix)
Clear approach to deliver growth ambitions

- World class portfolio
- Competitive capabilities
- Strategy to outperform
- Growth ambitions

Category-leading brands
Attractive geographic footprint
Growth sector
### World class portfolio of category leading brands

<table>
<thead>
<tr>
<th>Category</th>
<th>Revenue (2021)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral Health</td>
<td>£2.7bn</td>
</tr>
<tr>
<td>VMS</td>
<td>£1.5bn</td>
</tr>
<tr>
<td>Pain Relief</td>
<td>£2.2bn</td>
</tr>
<tr>
<td>Respiratory Health</td>
<td>£1.1bn</td>
</tr>
<tr>
<td>Digestive Health and other</td>
<td>£2.0bn</td>
</tr>
</tbody>
</table>

#### Local strategic brands

#### Power brands

1. **Therapeutic OH**
   - #1
   - #3

2. **Digestive Health**
   - #1

3. **Oral Health**
   - #1

4. **VMS**
   - #1

---

1. 2021 Haleon revenue
2. Euromonitor ‘Oral Care’ (2020)
3. Therapeutic OH from company analysis based on Nielsen and IRI (2020), Therapeutic OH includes therapeutic toothpaste and denture care, OH: Oral Health
4. Source: N. Hall (2020) for OTC and VMS; VMS: Vitamins, Minerals, Supplements
Attractive geographic footprint, well placed for growth

- **#1 or #2 OTC/VMS position** in 70% of markets¹

- Global #3 in Oral Health² with **leading position in Therapeutic Oral Health**³

- Good balance of **growth and stability**, with emerging markets c.1/3 of revenue⁴

---

¹ Nicholas Hall’s DB6 Consumer Healthcare (OTC/VMS) Database, 2020 Store and E-commerce sales. Note: Haleon position in OTC/VMS. Brazil #4 overall, South Africa #2 overall, Poland #4 overall, Philippines #2 overall, Turkey #3 overall. MNC=Multi-national Company. Germany is a statistical tie for #1.

² Euromonitor ‘Oral Care’ (2020)

³ Company analysis based on Nielsen and IRI (2020)

⁴ Haleon revenue 2021

Key: Bubble size approximates market size
A £150bn+ sector with expected 3-4% annual medium term growth

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>£25bn</td>
<td>£46bn</td>
<td>£15bn</td>
</tr>
<tr>
<td>Expected medium-term market growth (%)</td>
<td>3-4%</td>
<td>4-5%</td>
<td>2-3%</td>
</tr>
</tbody>
</table>

**HALEON outlook 4-6% organic annual sales growth**

---

1. Organic annual sales growth (see appendix for definition), in the medium term.
3. Source: OTC and VMS market size: Nicholas Hall (2020); Company internal analysis based on Nielsen, IRI, IQVIA, and N. Hall Data (2020).
4. Expected growth rates in Halcion’s current brand market footprint only. £150+bn sector refers to Consumer Healthcare, which includes Oral Health, VMS and OTC.
Clear approach to deliver growth ambitions

World class portfolio + Competitive capabilities + Strategy to outperform → Growth ambitions

- Human understanding + trusted science
- Proven brand-building and innovation
- Leading route-to-market
- Digital connectivity
Competitive advantage
Combining human understanding and trusted science

**Human Understanding**

Addressing **real consumer everyday health needs**

Educating on **better health solutions**

**Deep understanding** of consumer health needs and behaviour

**HCP\(^1\) engagement** enabling early understanding of consumer needs

**Inspiring innovations** to excite and make healthcare more enjoyable

---

**Trusted Science**

**Deep** technical and scientific talent

**World class** regulatory and medical expertise

**Clinical** trials and extensive studies experience

**Trusted relationships** with HCPs

**Leading** R&D capabilities and investment

---

\(^1\) HCP: healthcare professional
Proven competitive capabilities

Brand building

A&P investment 20% of revenue, competitive and driving growth

Innovation

R&D investment 3%1 of revenue, industry top quartile

Route-to-market

Direct relationships with c.3 million HCPs2

#1 pharmacy coverage

Strong mass retail and e-commerce

Data and digital increasing connectivity with consumers, customers and experts

1 2021 adjusted R&D expense
2 HCPs: healthcare professionals
Clear approach to deliver growth ambitions

- World class portfolio
- Competitive capabilities
- Strategy to outperform
- Growth ambitions

Household penetration

New and emerging opportunities

Strong execution and financial discipline

Responsible business
Significant penetration growth headroom across categories

1. Nearly **1 in 3** adults have experienced sensitive teeth, but only 1 in 3 of them purchased a sensitivity product.\(^1\)

2. **9 out of 10** people suffer from pain, but only 1 in 3 of them treat their pain immediately.\(^2\)

3. Calcium intake vs recommended level but only c.17% take calcium supplement.\(^3\)

---

\(^1\) Source: Oral Health Population Data – IPSOS Incidence Study Calculations 2015; figures are averages

\(^2\) Source: Edelman Intelligence, GPI 4, 2020, 19 markets, 19,000 respondents

\(^3\) Source: Penetration data from Kantar (2020)
Proven approach to drive penetration-led growth
Consistent outperformance of Sensodyne

Meaningful and distinctive brands
Category-driving innovation
Commercial excellence
Expert advocacy

>10% CAGR 2011-2021

1 Source: GSK Consumer Healthcare segment revenue growth, Sensodyne. 2011–2021
2 Experts are Healthcare Professionals
New and emerging growth: Channel expansion

E-commerce – a growing channel
Global e-commerce % of total sales (%)

Strong position in key markets with meaningful opportunity for growth
E-commerce % of sales in key markets in 2021 (%)

Well invested in key capabilities – innovation, optimised marketing, social influencers and commerce

Market and category development varies by country
Delivered strong double digit growth over last two years

Source: GSK Consumer Healthcare financial data
New and emerging growth: Geographic expansion

HALEON MARKET EXAMPLES

MIDDLE EAST AND AFRICA
- Double digit growth over the last 2 years
- >80% weighted distribution\(^3\)
- c.50% revenue

INDIA
- Strong double digit growth over the last 5 years
- >4 million retail stores
- >75% revenue

HALEON BRAND EXAMPLES

parodontax
- Gum health: a major condition
- Among the world’s fastest growing toothpaste brands\(^1\)

Centrum
- #1 multivitamins globally\(^2\)
- c.2/3 of revenue from 5 markets

---

1. Company analysis based on Nielsen and IRI data (2020)
2. Source: N. Hall (2020)
3. Weighted distribution: percentage of points of sale where a product is available, assigning to each point of sale, a weight proportional to its revenue
New and emerging growth: Portfolio expansion

**Rx-to-OTC switch**

- 4 switches in the US over last 8 years, more than any competitor
- **2 new deals agreed** driving the Rx-to-OTC pipeline, expected launches 2025/26
- **Attractive partner** for switch given track record, dedicated resources and strong routes to market

**Accelerating consumer trends: Naturals**

- **Naturals growing faster** than the sector average
- Significant **demand from younger consumers** across prevention, treatment and recovery
- **10 launches** in the last 12 months
- **Over 30 projects in the pipeline**
**Performance underpinned by strong execution and financial discipline**

<table>
<thead>
<tr>
<th>Quality and supply chain</th>
<th>Marketing execution</th>
<th>Commercial execution</th>
<th>Cost and cash discipline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manufacturing sites from 41 in 2015 to 24 in 2021</td>
<td>Increased reinvestment into A&amp;P +£0.2bn in 2019-2021&lt;sup&gt;2&lt;/sup&gt;</td>
<td>Optimising strength in key route-to-market channels</td>
<td>Driving +325bps adjusted operating margin expansion over 2 years&lt;sup&gt;4&lt;/sup&gt;</td>
</tr>
<tr>
<td>&gt;80% products sold are locally&lt;sup&gt;1&lt;/sup&gt; sourced</td>
<td>Increasing effectiveness with digital media spend c.50%</td>
<td>Retail execution standard and Pharmacy CRM driving effective execution</td>
<td>c.£3.2bn free cash flow generation over 2 years&lt;sup&gt;5&lt;/sup&gt;; high cash conversion</td>
</tr>
<tr>
<td>&gt;200 successful regulatory inspections over 2 years</td>
<td>70% rationalisation of creative / production partners</td>
<td>Net Revenue Management driving 2.2%/1.8% price/volume mix&lt;sup&gt;3&lt;/sup&gt;</td>
<td>Over-delivery on integration synergy target</td>
</tr>
</tbody>
</table>

---

<sup>1</sup> Local defined as geographies with proximity, i.e. North America, Latin America, Europe, Middle East and Africa, India, China, Southeast Asia, Australia and New Zealand, Japan and Korea

<sup>2</sup> A&P is excluding brands divested, synergies and FX movements

<sup>3</sup> 2021 vs 2020, based on Haleon revenue

<sup>4</sup> Adjusted operating margin at actual rates, 2021 vs 2019

<sup>5</sup> 2020 and 2021 (see appendix for definition)
Running a responsible business, integral to all we do

Our purpose and brands position us to have **positive impact**

**Environmentally strong foundation** and structurally advantaged footprint to play a positive role

Well positioned to make a difference in **health inclusivity**

Setting ambitious targets for **Inclusion, Equity** and **Diversity**

Committed to building **strong corporate governance**
### Structurally advantaged environmental footprint

#### 2020 carbon footprint scope 1-3 (mn tonnes CO2e)
Comparison vs global household and personal care peers

<table>
<thead>
<tr>
<th></th>
<th>Peer 1</th>
<th>Peer 2</th>
<th>Peer 3</th>
<th>Peer 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020</td>
<td>36.0</td>
<td>42.0</td>
<td>61.0</td>
<td>197.0</td>
</tr>
</tbody>
</table>

#### 2020 Carbon intensity scope 1-3 (kg CO2e / £ revenue)
Comparison vs global household and personal care peers

<table>
<thead>
<tr>
<th></th>
<th>Peer 1</th>
<th>Peer 2</th>
<th>Peer 3</th>
<th>Peer 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020</td>
<td>0.2</td>
<td>1.4</td>
<td>2.6</td>
<td>3.3</td>
</tr>
</tbody>
</table>

1 Comparison vs global household and personal care peers, including P&G, Reckitts, Unilever, Colgate
Clear approach to deliver growth ambitions

- World class portfolio
  - Category-leading brands
  - Attractive geographic footprint
  - Growth sector

- Competitive capabilities
  - Human understanding + trusted science
  - Proven brand-building and innovation
  - Leading route-to-market
  - Digital connectivity

- Strategy to outperform
  - Household penetration
  - New and emerging opportunities
  - Strong execution and financial discipline
  - Responsible business

Growth ambitions

4-6% organic annual sales growth\(^1\)

Expanding margin\(^2\) while investing for growth

High cash conversion\(^3\)

Disciplined capital allocation

---

\(^1\) Organic annual sales growth (see appendix for definition), in the medium term

\(^2\) Adjusted operating margin, in the medium term at CER

\(^3\) Free cash flow conversion (see appendix)
Focused plan to deliver 4-6% organic annual sales growth

- Market growth at c.2% with the pandemic impact
- Portfolio and geographic footprint reshaped and well positioned for growth
- Competitive capabilities
- Optimised and agile operating model
- Integration and separation preparation

4.4% CAGR

Growth categories and geographies driving increasing contribution

- Strategic building blocks: Increased penetration and channel/geography/portfolio expansion
- A&P and R&D investment ahead of sales growth
- Focused and strong execution

2019-2021

Medium Term

4-6%³

1 Company analysis based on external data (Nielsen, IRI, IQVIA and N. Hall), 2019 - Nov YTD 2021
3 Organic annual sales growth (see appendix for definition), in the medium term
## Margin expansion while investing for growth

<table>
<thead>
<tr>
<th>Drivers</th>
<th>Medium-term trajectory¹</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gross Margin</strong></td>
<td>↑</td>
</tr>
<tr>
<td>Positive mix and pricing</td>
<td></td>
</tr>
<tr>
<td>COGS efficiencies</td>
<td></td>
</tr>
<tr>
<td><strong>A&amp;P</strong></td>
<td>↑</td>
</tr>
<tr>
<td>A&amp;P spend ahead of sales growth</td>
<td></td>
</tr>
<tr>
<td>A&amp;P efficiency and effectiveness</td>
<td></td>
</tr>
<tr>
<td><strong>R&amp;D</strong></td>
<td>↑</td>
</tr>
<tr>
<td>R&amp;D investment ahead of sales growth</td>
<td></td>
</tr>
<tr>
<td>Increased returns on R&amp;D spend</td>
<td></td>
</tr>
<tr>
<td><strong>Other SG&amp;A</strong></td>
<td>↓</td>
</tr>
<tr>
<td>Continued efficiency and optimisation</td>
<td></td>
</tr>
<tr>
<td><strong>Adjusted Operating Margin</strong></td>
<td>↑</td>
</tr>
<tr>
<td>Sustainable moderate margin expansion</td>
<td></td>
</tr>
</tbody>
</table>

¹ Adjusted results at CER
Sustainable model driving investment for growth and attractive returns

- 4-6% organic annual sales growth
- High gross margin and cost discipline
- Increasing investment in A&P and innovation
- Sustainable moderate margin expansion
- High cash conversion
- Dividend and deleverage
- Strong investment grade balance sheet

1 Organic annual sales growth (see appendix for definition), in the medium term
2 Adjusted operating margin, in the medium term at CER
3 Free cash flow conversion (see appendix)
Growth focused disciplined capital allocation

1. Reinvest in business
   - Focused reinvestment to drive sustainable growth and attractive returns

2. Dividend
   - Initial dividend expected to be at the lower end of the 30-50% payout range, subject to HALEON Board approval

3. M&A
   - Where commercially compelling and consistent with company strategy

Target net debt / EBITDA of <3x by the end of 2024

Maintain strong investment grade balance sheet

---

1. 30-50% of profit attributable to shareholders
2. Adjusted EBITDA
Global leader 100% focused on consumer healthcare with clear purpose

Exceptional portfolio of category leading brands with attractive footprint and competitive capabilities

Strategy to outperform and run a responsible business, integral to all we do

4-6% organic annual sales growth\(^1\), sustainable moderate margin\(^2\) expansion and high cash conversion\(^3\)

Attractive growth profile with capacity to invest and deliver shareholder returns

---

\(^1\) Organic annual sales growth (see appendix for definition), in the medium term
\(^2\) Adjusted operating margin, in the medium term at CER
\(^3\) Free cash flow conversion (see appendix)
Thank you
Assumptions and cautionary statement and regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2020, GSK's 2021 Q4 Results and any impacts of the COVID-19 pandemic.

In outlining the medium term outlooks, growth ambitions and 2022 considerations for Haleon, GSK has made certain assumptions about the consumer healthcare sector, the different geographic markets and product categories in which Haleon operates and the delivery of revenues and financial benefits from its current product range, pipeline and integration and restructuring programmes. These assumptions, as well as the outlooks, ambitions or considerations (as applicable) for organic annual sales growth, adjusted operating margin expansion, dividend payout ratio, cash generation/conversion and deleveraging, assume, among other things, no material interruptions to the supply of Haleon's products, no material mergers, acquisitions or disposals, no material litigation or investigation costs (save for those that are already recognised or for which provisions have been made), no material changes in the regulatory framework for developing new products and retaining marketing approvals, no material changes in the healthcare environment, no unexpected significant changes in Haleon's end markets, no unexpected significant changes in pricing as a result of government, customer or competitor action, and no material changes in the impacts of the COVID-19 pandemic. These outlooks, ambitions and considerations also assume the successful delivery of the separation programme to deliver the demerger of Haleon and the realisation of its anticipated benefits. The outlook, growth ambitions and 2022 considerations are given at constant exchange rates.
Executing portfolio strategy to build focused scale and leadership

- **2012**
  - Divest Non-strategic OTC

- **2013**
  - Divest
    - Exit of beverages: Lucozade and Ribena to Suntory

- **2015**
  - JV formation

- **2018**
  - Buy out
    - Full buy out of Novartis from JV

- **2019**
  - Significant divestment programme
    - Non-strategic and growth dilutive OTC and skin assets disposal, £1.1bn proceeds

- **2020**
  - Divest
    - Exit of non-strategic categories to Unilever

- **2021**

1. Horlicks not part of JV
2. Target demerger date July 2022
3. Net proceeds
Favourable underlying sector growth fundamentals

- Increased consumer focus on health and wellness
- Emerging middle class
- Ageing population
- Increasing pressure on public healthcare systems
- Unmet consumer needs
## World class portfolio of category-leading brands

<table>
<thead>
<tr>
<th>Category</th>
<th>Brand</th>
<th>Revenue 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral Health</td>
<td>Sensodyne</td>
<td>£2.7bn</td>
</tr>
<tr>
<td>VMS</td>
<td>Centrum</td>
<td>£1.5bn</td>
</tr>
<tr>
<td>Pain Relief</td>
<td>Panadol</td>
<td>£2.2bn</td>
</tr>
<tr>
<td>Respiratory Health</td>
<td>Theraflu</td>
<td>£1.1bn</td>
</tr>
<tr>
<td>Digestive Health</td>
<td>Ofrivin</td>
<td>£2.0bn</td>
</tr>
</tbody>
</table>

- **Power brands**
  - Sensodyne
  - Parodontax
  - Centrum
  - Panadol
  - Advil
  - Voltaren
  - Ofrivin

- **Local strategic brands**
  - Dr. Best
  - Emergen-C
  - Excedrin
  - Robitussin
  - ChapStick
  - Eno

---

1. GSK Consumer Healthcare segment sales 2021
2. Euromonitor 'Oral Care' (2020), OH: Oral Health
3. Therapeutic OH from company analysis based on Nielsen and IRI (2020), Therapeutic OH includes therapeutic toothpaste and denture care
4. Source: N. Hall (2020) for OTC and VMS; VMS: Vitamins, Minerals, Supplements
#1 in Therapeutic Oral Health
Creating a premium, fast growing category

The world’s leading sensitivity toothpaste¹, and #2 overall toothpaste²

Among the world’s fastest growing global toothpaste brands³

The world’s leading denture care brand, sold across 60+countries²

¹ Company analysis (2020)
² Source: Euromonitor (2020)
³ Company analysis based on Nielsen and IRI data (2020)
#1 in Vitamins, Minerals and Supplements
Enabling proactive everyday health

The world’s leading and the most clinically studied multivitamins¹

#1 vitamin C and immunity supplement in the US

Leading brand for bone and joint supplements in China

Source: N. Hall (2020)
¹ Company analysis for “most clinically studied multivitamins”
#1 in Pain Relief
Leader across ingredients and formats

The world's leading topical pain relief brand and #3 largest OTC brand globally

The world’s #2 pain relief brand in the US and #4 largest OTC brand globally

Leading systemic pain relief brand outside the US – sold across over 90 countries

Source: N. Hall (2020)
#1 in Respiratory Health

Presence across key conditions

Europe’s #2 and North America’s #3 oral cold and flu brand – in over 50 markets

The world’s leading topical decongestant brand

Leading allergy remedy in the USA

Source: N. Hall (2020)
#1 in Digestive Health
Well-loved brands and consumer preferred formats

Leading OTC heartburn treatment in the USA with more than 90 years heritage

#1 OTC heartburn treatment in India and Brazil with more than 100 years of heritage

Source: N. Hall (2020)
### Haleon financial reporting considerations

#### IFRS Income Statement

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>£m</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>North America</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>3,525</td>
<td></td>
</tr>
<tr>
<td>Adjusting items</td>
<td>(77)</td>
<td></td>
</tr>
<tr>
<td><strong>EMEA &amp; LatAm</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>3,877</td>
<td></td>
</tr>
<tr>
<td>Adjusting items</td>
<td>(534)</td>
<td></td>
</tr>
<tr>
<td><strong>APAC</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>2,143</td>
<td></td>
</tr>
<tr>
<td><strong>Corporate &amp; Unallocated</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjusting items</td>
<td>(534)</td>
<td></td>
</tr>
</tbody>
</table>

#### Reportable segments

<table>
<thead>
<tr>
<th>Region</th>
<th>2021</th>
<th>£m</th>
</tr>
</thead>
<tbody>
<tr>
<td>North America</td>
<td>2021</td>
<td>£m</td>
</tr>
<tr>
<td>Revenue</td>
<td>3,525</td>
<td></td>
</tr>
<tr>
<td>Adj. Op. Margin</td>
<td>23.5%</td>
<td></td>
</tr>
<tr>
<td>EMEA &amp; LatAm</td>
<td>2021</td>
<td>£m</td>
</tr>
<tr>
<td>Revenue</td>
<td>3,877</td>
<td></td>
</tr>
<tr>
<td>Adj. Op. Margin</td>
<td>24.8%</td>
<td></td>
</tr>
<tr>
<td>APAC</td>
<td>2021</td>
<td>£m</td>
</tr>
<tr>
<td>Revenue</td>
<td>2,143</td>
<td></td>
</tr>
<tr>
<td>Adj. Op. Margin</td>
<td>21.5%</td>
<td></td>
</tr>
</tbody>
</table>

#### Revenue on a Category basis

1. See glossary for definition of Adjusted measures
2. Revenue, revenue growth, revenue growth at CER and organic revenue growth (see glossary for definition) will be published for the reportable segments and categories
Comparison of Haleon to GSK segment financials

Whilst a part of GSK, Haleon has historically been reported as an operating segment under IFRS 8 in GSK’s annual report and interim financial reporting (the “CH Segment”). The financial information presented above has been prepared in a manner consistent with the Historical Financial Information prepared in connection with the anticipated demerger and separation of Haleon from GSK and therefore differs both in purpose and basis of preparation to the CH Segment as presented historically in GSK’s financial reporting. As a result, whilst the two sets of financial information are similar, they are not the same because of certain differences in accounting and disclosure under IFRS.

These differences primarily include:

(1) the inclusion in GSK’s segment reporting of certain distribution and local commercial activities performed by a limited number of other GSK Group entities in relation to Consumer Healthcare products

(2) the basis of allocation of certain cost-sharing and royalty agreements as attributed by a limited number of other GSK Group entities for the purposes of GSK segment reporting

(3) the inclusion of Horlicks and other Consumer Healthcare nutrition products in India and certain other markets in GSK segment reporting

(4) the sale of Thermacare products until their disposal in 2020 which have been excluded from GSK segment reporting

Key figures (£m)

<table>
<thead>
<tr>
<th></th>
<th>Haleon¹</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>8,480</td>
<td>9,892</td>
<td>9,545</td>
<td>8,995</td>
<td>10,033</td>
</tr>
<tr>
<td>Adjusted</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operating</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Profit³</td>
<td>1,654</td>
<td>2,074</td>
<td>2,172</td>
<td>1,874</td>
<td>2,213</td>
</tr>
<tr>
<td>Adjusted</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operating</td>
<td>19.5%</td>
<td>21.0%</td>
<td>22.8%</td>
<td>20.8%</td>
<td>22.1%</td>
</tr>
<tr>
<td>margin³</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

¹ Haleon financial results
² GSK Consumer Healthcare segment financial results
³ See glossary for definition of Adjusted measures
# Revenue Reconciliation

Haleon portfolio growth reflects the growth of Haleon’s brands during the track record period.

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue £bn</td>
<td>8.5</td>
<td>9.9</td>
<td>9.5</td>
</tr>
<tr>
<td>Growth %</td>
<td>n/a</td>
<td>16.7%</td>
<td>(3.5%)</td>
</tr>
<tr>
<td>Growth CER %</td>
<td>n/a</td>
<td>19.3%</td>
<td>1.0%</td>
</tr>
<tr>
<td>Organic revenue growth %</td>
<td>n/a</td>
<td>2.8%</td>
<td>3.8%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2020</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue growth %</td>
<td>16.7%</td>
<td>(3.5%)</td>
</tr>
<tr>
<td>Organic growth adjustments of which:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Effect of acquisitions</td>
<td>(16.6%)</td>
<td>2.7%</td>
</tr>
<tr>
<td>Effect of divestments</td>
<td>(19.7%)</td>
<td>-</td>
</tr>
<tr>
<td>Effect of manufacturing service agreements (MSAs)²</td>
<td>(0.1%)</td>
<td>0.0%</td>
</tr>
<tr>
<td>Effect of exchange rates</td>
<td>2.7%</td>
<td>4.6%</td>
</tr>
<tr>
<td>Organic revenue growth %</td>
<td>2.8%</td>
<td>3.8%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haleon portfolio revenue £bn</td>
<td>9.5</td>
</tr>
<tr>
<td>Growth %</td>
<td>n/a</td>
</tr>
<tr>
<td>Growth CER %</td>
<td>n/a</td>
</tr>
</tbody>
</table>

Haleon portfolio revenue and growth illustrate the performance of the brands that make up the portfolio at spin to provide the best understanding of the size and growth of Haleon’s brands during the track record period.

Haleon portfolio revenue and growth are presented here to aid understanding but become unnecessary going forward. Instead revenue, revenue growth, revenue growth at CER and organic growth will be used.

Source: Company analysis

¹ See glossary for definitions
² Manufacturing service agreements ("MSAs") relating to divestments and the closure of sites or brands

---


Haleon portfolio growth differs from organic growth in two key respects:
(1) By including 12 months of Pfizer brand sales in all years (including 2019)
(2) By completely excluding all sales of brands divested from all years
### IFRS and Adjusted Income Statement

#### 2020 (£m)

<table>
<thead>
<tr>
<th></th>
<th>IFRS Result</th>
<th>Net Intangible Amortisation and Impairment</th>
<th>Restructuring Costs</th>
<th>Transaction Related Costs</th>
<th>Separation and Admission Costs</th>
<th>Disposal and others</th>
<th>Adjusted Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>9,892</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>9,892</td>
</tr>
<tr>
<td>Cost of Sales</td>
<td>(3,982)</td>
<td>81</td>
<td>89</td>
<td>91</td>
<td>2</td>
<td>(3,719)</td>
<td></td>
</tr>
<tr>
<td>Gross Profit</td>
<td>5,910</td>
<td>81</td>
<td>89</td>
<td>91</td>
<td>2</td>
<td>6,173</td>
<td></td>
</tr>
<tr>
<td>% Gross Margin</td>
<td>59.7%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>62.4%</td>
</tr>
<tr>
<td>Selling, general and admin</td>
<td>(4,220)</td>
<td>314</td>
<td>66</td>
<td>21</td>
<td>(3,819)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research and development</td>
<td>(304)</td>
<td>16</td>
<td></td>
<td></td>
<td></td>
<td>(280)</td>
<td></td>
</tr>
<tr>
<td>Other operating income</td>
<td>212</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(212)</td>
<td>0</td>
</tr>
<tr>
<td>Operating Profit</td>
<td>1,598</td>
<td>97</td>
<td>411</td>
<td>91</td>
<td>66</td>
<td>(189)</td>
<td>2,074</td>
</tr>
<tr>
<td>% Margin</td>
<td>16.2%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>21.0%</td>
</tr>
<tr>
<td>Finance income</td>
<td>20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Finance expense</td>
<td>(27)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Profit before taxation</td>
<td>1,591</td>
<td>97</td>
<td>411</td>
<td>91</td>
<td>66</td>
<td>(189)</td>
<td>2,067</td>
</tr>
<tr>
<td>Taxation</td>
<td>(410)</td>
<td>(19)</td>
<td>(90)</td>
<td>(20)</td>
<td>(13)</td>
<td>69</td>
<td>(483)</td>
</tr>
<tr>
<td>Tax rate %</td>
<td>25.8%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>23.4%</td>
</tr>
<tr>
<td>Profit after tax for the year</td>
<td>1,181</td>
<td>78</td>
<td>321</td>
<td>71</td>
<td>53</td>
<td>(120)</td>
<td>1,584</td>
</tr>
</tbody>
</table>

#### 2021 (£m)

<table>
<thead>
<tr>
<th></th>
<th>IFRS Result</th>
<th>Net Intangible Amortisation and Impairment</th>
<th>Restructuring Costs</th>
<th>Transaction Related Costs</th>
<th>Separation and Admission Costs</th>
<th>Disposal and others</th>
<th>Adjusted Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>9,545</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>9,545</td>
</tr>
<tr>
<td>Cost of Sales</td>
<td>(3,595)</td>
<td>8</td>
<td>44</td>
<td></td>
<td></td>
<td></td>
<td>(3,543)</td>
</tr>
<tr>
<td>Gross Profit</td>
<td>5,950</td>
<td>8</td>
<td>44</td>
<td></td>
<td></td>
<td></td>
<td>6,002</td>
</tr>
<tr>
<td>% Gross Margin</td>
<td>62.3%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>62.9%</td>
</tr>
<tr>
<td>Selling, general and admin</td>
<td>(4,086)</td>
<td>-</td>
<td>150</td>
<td></td>
<td></td>
<td></td>
<td>(3,582)</td>
</tr>
<tr>
<td>Research and development</td>
<td>(257)</td>
<td>8</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td>(248)</td>
</tr>
<tr>
<td>Other operating income</td>
<td>31</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(31)</td>
<td>-</td>
</tr>
<tr>
<td>Operating Profit</td>
<td>1,638</td>
<td>16</td>
<td>195</td>
<td></td>
<td></td>
<td></td>
<td>2,172</td>
</tr>
<tr>
<td>% Margin</td>
<td>17.2%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>22.8%</td>
</tr>
<tr>
<td>Finance income</td>
<td>17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Finance expense</td>
<td>(19)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Profit before taxation</td>
<td>1,636</td>
<td>16</td>
<td>195</td>
<td></td>
<td></td>
<td></td>
<td>2,170</td>
</tr>
<tr>
<td>Taxation</td>
<td>(197)</td>
<td>8</td>
<td>(36)</td>
<td></td>
<td></td>
<td>(197)</td>
<td>(469)</td>
</tr>
<tr>
<td>Tax rate %</td>
<td>12.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>21.6%</td>
</tr>
<tr>
<td>Profit after tax for the year</td>
<td>1,439</td>
<td>24</td>
<td>159</td>
<td>231</td>
<td>(152)</td>
<td></td>
<td>1,701</td>
</tr>
</tbody>
</table>

---

1. See glossary for definitions of Adjusting Items and comments regarding the use of Adjusted measures.
Haleon divestments

Revenue of divested brands (£bn; 2019-2021)\(^1\)

- **2019**: 0.5
- **2020**: 0.3
- **2021**: <0.05

---

Brands divested 2019-2021\(^3\)

- **2019**
  - Bialcol, Ceridal, Cibalgin, Eurax, Keri, Magnesia Bisurada\(^4\), Oiilatum, Polytar/Tarmed, Prevacid, Savlon, Tixylix

- **2020**
  - Alavert, Anbesol, Argus, Boost\(^5\), Breathe Right, Capent, Cetebe, Cholinex, Clindo, Coldrex, Dimetapp, Dristan, Duofilm, Eclipsol, Fibercon, Hinds\(^3\), Horlicks\(^5\), KCI-retard\(^6\), Lemocin, Mebucaine, Omega/Fri-Flyt, Orofar, Physiogel, Primatene, Pulmex, Resyl, Sunmax, Sweatosan, Synthol, Tavegyl, Thermacare, Tossamin, Trofolastin, Venoruton, Viva/Maltova

- **2021**
  - Acne-Aid, Baldriparan, Formigran, Kamol, KCI-retard\(^6\), Spalt, Spectran, Transderm scop

---

1. Excludes revenue of Horlicks/ Boost, which were excluded from the Haleon perimeter
2. On a reported basis including 5 months’ August–December revenue of Pfizer brands
3. Brands are listed by year of closing of divestment
4. Partial divestment
5. Horlicks/Boost was excluded from the Haleon perimeter and financials but was included in GSK plc’s CH segment reporting. Horlicks revenue was £0.5bn in 2019
6. Partially divested across 2020-2021
Glossary

A number of Adjusted measures are used to report the performance of our business which are non-IFRS measures. Adjusted results, CER and other non-IFRS measures may be considered in addition to, but not as a substitute for or superior to, information presented in accordance with IFRS. These measures are defined and set out below. Reconciliations to the nearest IFRS measure will be provided as part of the Historical Financial Information as part of the Prospectus.

Adjusted EBITDA is defined as profit after tax for the year excluding income tax, finance income, finance expense, Adjusting Items (as defined below), depreciation of property plant and equipment, impairment of property plant and equipment net of reversals, depreciation of right-of-use assets, and amortisation of software intangibles.

Adjusting Items include the following:

- **Net amortisation and impairment of intangible assets**: Intangible amortisation and impairment of goodwill, brands, licenses and patents net of impairment reversals.

- **Restructuring costs**: include personnel costs associated with restructuring programs, impairments of tangible assets and computer software relating to specific programmes approved by the Board from time to time that are structural and of a significant scale, where the costs of individual or related projects exceed £15 million. These costs also include integration costs following an acquisition.

- **Separation and admission costs**: costs incurred in relation to and in connection with the demerger, separation, admission and registration of Haleon Shares.

- **Transaction related costs**: Accounting or other adjustments related to significant acquisitions.

- **Disposal and other adjusting items**: Gains and losses on disposals of assets and businesses, tax indemnities related to business combinations, and other items.

Adjusted Operating Profit is defined as operating profit less Adjusting Items as defined above.

Compound Annual Growth Rate (CAGR) represents the annualised average rate of growth between two given years assuming growth takes place at a compounded rate.

Free cash flow is defined as net cash inflow from operating activities plus cash inflows from the sale of intangible assets, the sale of property, plant and equipment and interest received, less cash outflows for the purchase of intangible assets, the purchase of property, plant and equipment, distributions to non-controlling interests and interest paid.

Free cash flow conversion is defined as free cash flow, as defined above, divided by profit after tax.

Haleon portfolio revenue represents the revenue of the brands that make up the Company’s portfolio at separation from GSK. The measure includes 12 months revenue of Pfizer brands in all years including 2019 and excludes all revenue of divested / closed brands from all years. It also excludes revenue attributable to manufacturing service agreements (“MSAs”) relating to divestments and the closure of sites or brands. Haleon portfolio revenue is presented here to aid understanding but will not be used going forward.

Haleon portfolio revenue growth represents the growth in Haleon portfolio revenue excluding the impact of exchange movements.

Organic revenue growth represents revenue growth, as determined under IFRS and excluding the impact of acquisitions, divestments and closures of brands or businesses, revenue attributable to manufacturing service agreements (“MSAs”) relating to divestments and the closure of sites or brands, and the impact of currency exchange movements.

Organic sales growth is the same as organic revenue growth (as defined above) and the terms are used interchangeably in these materials.

Sales is the same as revenue and the terms are used interchangeably in these materials.